The National Institutes of Health Renews License With Bioalma in Multi-Year Deal

MADRID, SPAIN, May 18 (MARKET WIRE) --
Bioalma today announced that the National Institutes of Health (NIH) has
licensed AlmaKnowledgeServer 2 (AKS2) software, the company's informatics
system which contains powerful tools to search, analyze, and visualize
all types of information extracted from biomedical literature. AKS2 is a
subscription-based system, and is the technology that is the basis for
Bioalma's free biomedical search tool -- novo|seek.

The Center for Information Technology (CIT) at the NIH has expanded its
licenses of AKS2 by more than 25 percent to ensure that researchers
involved in the human salivary proteome project can utilize the solution
as the annotation platform for the project -- a project with a long-term
goal of supporting the discovery of saliva-based diagnostic tests.
Saliva-based tests hope to provide new "non-invasive" diagnostic methods
that can be performed for little cost in a doctor's office or at a
patient's home.

"Being selected yet again by the NIH -- the go-to resource for biomedical
research in the US -- is a proof point to the powerful capabilities behind
our text mining technology -- within both AKS2 and novo|seek," said Ramon
Alonso-Allende, director of marketing and business development, Bioalma.
"Our overarching goal is to put the power of information into the hands
of researchers, medical students, doctors, and librarians, and we
continue to add functionality and expanded resources to our family of
biomedical search tools to solve that ever-increasing problem of mining
overwhelming amounts of scientific literature."

Bioalma will be exhibiting novo|seek -- a powerful alternative to
traditional information retrieval systems aimed at a variety of audiences
within the biomedical community -- at the Bio International Convention
this week at booth #1405/M06.

Tags/keywords: biomedical research, National Institutes of Health, NIH,
research, novo|seek, AKS2

Supporting Resources:

To download the Bioalma corporate backgrounder, please visit:
www.novoseek.com/info/ns_backgrounder.html

For information on AKS2: http://www.bioalma.com/aks2/index.php

For more information on novo|seek, visit:

blog: http://blog.novoseek.com/

Twitter feed: http://twitter.com/novoseek/

Facebook group: http://www.facebook.com/pages/novoseek/101834395337

LinkedIn group: http://www.linkedin.com/groups?gid=1699237&trk=hb_side_g

About novo|seek

Novo|seek is a dynamic information extraction system for searching the
published knowledge in biomedical literature.

Novo|seek indexes the biomedical literature with text mining technology
built by Bioalma that identifies key biomedical terms taking into account
external available data and contextual term information. As a result of
this indexing technology, novo|seek retrieves every document where a term
is mentioned no matter the synonym used and discards those documents where
the term is used with an unwanted meaning.

About Bioalma

Located in Madrid, Spain, Bioalma is an IT company specialized in the
research and development of biomedical software.

Bioalma was founded in 2000 as a spin-off of a bioinformatics group in the
National Center of Biotechnology and a privately-held company, as part of
the Bionostra group. Bioalma prides itself on an elite team of well-known,
internationally-leading scientists as part of its scientific committee and
has successfully marketed its technology to different research
institutions, universities, pharmaceutical and biotech companies,
including National Institutes of Health, Universidad Nacional Autonoma de
Mexico, Roche and Althea Technologies.

Bioalma is a privately-owned company, part of the Bionostra group. The
Bionostra Group is composed of four companies that share the common
objective of being leaders in the biotechnology and bioinformatics
sectors. Its main activity is scientific research focused on the
development of new technologies, products and biotechnology services
within the field of human health. Bionostra Group is composed of Bioalma,
ChimeraPharma, Bionostra and Microbionta.

Copyright 2009, Market Wire, All rights reserved.

-0-